Company intelligence / Profile preview
Liminal BioSciences Inc.
Belleville, Ontario, Canadaliminalbiosciences.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Liminal BioSciences is advancing its lead candidate LMNL6511, a GPR84 antagonist, to Phase 1 clinical trials. The company has also nominated LMNL6326 as its lead OXER1 antagonist candidate for eosinophil-driven diseases. Both programs are part of the company's focus on developing novel small molecule therapeutics targeting GPCRs for metabolic, inflammatory, and fibrotic diseases.
- Therapeutic areas
- GastroenterologyPulmonologyMetabolic DisordersNephrologyImmunologyEndocrinologyDermatologyRare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
Beyond the preview
Go deeper on Liminal BioSciences Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liminal BioSciences Inc..